Replies to post #3893 on Catalyst Pharmaceutical Partners (CPRX)

[hump4]

Sure. I didn't think of copying and pasting the content. Will do next time.

[hump4]

Roth Capital raised its price target on Catalyst Pharmaceutical Partners (NASDAQ: CPRX) to $6.00 (from $4.75) while maintaining a Buy rating following 4Q release. CPRX reported a 4Q EPS loss of $0.06, versus a targeted loss of $0.07. The company reached agreement with the FDA under a Special ...https://www.streetinsider.com/Analyst+Comments/UPDATE%3A+Catalyst+Pharmaceutical+Partners+%28CPRX%29+PT+Raised+to+%246+at+Roth+Capital+Following+4Q/13962031.html